Nasal Decongestant Composition Using Adrenergic and Steroid Synergy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for nasal congestion often require precise dosing and adherence to strict regimens, leading to potential over-medication, side effects, and rebound issues, particularly in patients with cardiovascular disorders.

Innovation Solution

Decongestant compositions comprising a safe and effective amount of an adrenergic compound and a steroid, administered in a pharmaceutically acceptable carrier, specifically formulated to reduce nasal mucosa swelling and alleviate congestion, with dosing flexibility and reduced side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If decongestant treatments are administered at higher doses to provide speedy recovery, then congestion relief is improved, but side effects and rebound issues increase

Engineering Contradiction:

Improvespeed of congestion reliefVSAvoidside effects and rebound issues

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the decongestant by combining adrenergic compounds with steroids or antihistamines. This chemical modification allows the treatment to achieve effective congestion relief while reducing the side effects and rebound issues associated with conventional high-dose decongestants. The synergistic interaction between the combined agents enables lower effective doses to achieve the same therapeutic effect.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite decongestant formulation by combining adrenergic compounds with steroids or antihistamines in specific ratios. This composite approach leverages the complementary mechanisms of action of different drug classes to achieve effective congestion relief while minimizing the harmful effects associated with single-agent high-dose therapy.

Inventive Principle:

Principle #40Composite materials

2Reliability

If precise dosing regimens are required to avoid side effects, then safety is improved, but ease of operation deteriorates due to strict adherence requirements

Engineering Contradiction:

Improvesafety from side effectsVSAvoidadherence to dosing regimen

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent modifies the dosing parameters by establishing specific concentration ranges for adrenergic compounds (0.01-5% w/v) combined with steroids or antihistamines. These optimized parameters provide a therapeutic window that maintains safety while allowing greater flexibility in dosing frequency and amount, reducing the burden of strict regimen adherence.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces dynamic dosing flexibility within defined safety parameters. The combined formulation allows patients to adjust dosing frequency and amount within a safe range, transforming the rigid dosing schedule into a more adaptable regimen that maintains safety while improving ease of operation.

Inventive Principle:

Principle #15Dynamics

3Productivity

If conventional decongestants are used to treat congestion, then nasal passage opening is improved, but tissue swelling returns after medication wears off

Engineering Contradiction:

Improvenasal passage patencyVSAvoidduration of congestion relief

Core Design Contradiction:

ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary action by including steroids or antihistamines that address the underlying inflammatory or allergic mechanisms before congestion fully develops. This preventive component works continuously to reduce nasal mucosa inflammation, preventing rebound swelling while the adrenergic compound provides immediate decongestion.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent ensures continuous therapeutic action through the combined formulation. The steroid or antihistamine component provides continuous anti-inflammatory or anti-allergic effect, while the adrenergic compound provides sustained vasoconstriction. This continuous dual-action mechanism prevents the waxing and waning of effect seen with conventional decongestants.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions effectively decrease congestion, enhance respiratory function, reduce side effects, and allow for personalized dosing, making them suitable for patients with cardiovascular disorders, while minimizing the amount of medication required.

Implementation Method 1

Decongestants act to constrict blood vessels in the nasal mucosa and thereby decrease tissue swelling and nasal congestion

Methodology Applied

Scientific EffectVasoconstriction:

Implementation Method 2

Steroids similarly reduce inflammation of swollen nasal mucosa

Methodology Applied

Scientific EffectAnti-inflammatory effect:

Data Source

PatentUS9737550B2Treatment of congestion using steroids and adrenergics

Publication Date: 2017.08.22 WANDZEL RICHARD A

AI summary

A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition comprising: (a) an adrenergic compound; and (b) a steroid; where the daily dose of the adrenergic compound administered to the subject is from about 1 μg to about 800 μg, and the daily dose of the steroid administered to the subject is from about 1 μg to about 400 μg.